| Title: |
Asthma management and control in children, adolescents and adults: Global Asthma Network (GAN) Phase I cross-sectional study |
| Authors: |
García-Marcos, L; Chiang, C-Y; Asher, MI; Marks, GB; El Sony, A; Masekela, R; Bissell, K; Ellwood, E; Ellwood, P; Pearce, N; Strachan, DP; Mortimer, K; Morales, E; Global Asthma Network Phase I Study Group |
| Publisher Information: |
Elsevier |
| Publication Year: |
2023 |
| Collection: |
St George's University of London: Repository |
| Description: |
Background Asthma is one of the most common non-communicable diseases globally. This study aimed to assess asthma medicine use, management plan availability, and disease control in childhood, adolescence, and adulthood across different country settings. Methods We used data from the Global Asthma Network Phase I cross-sectional epidemiological study (2015–20). A validated, written questionnaire was distributed via schools to three age groups (children, 6–7 years; adolescents, 13–14 years; and adults, ≥19 years). Eligible adults were the parents or guardians of children and adolescents included in the surveys. In individuals with asthma diagnosed by a doctor, we collated responses on past-year asthma medicines use (type of inhaled or oral medicine, and frequency of use). Questions on asthma symptoms and health visits were used to define past-year symptom severity and extent of asthma control. Income categories for countries based on gross national income per capita followed the 2020 World Bank classification. Proportions (and 95% CI clustered by centre) were used to describe results. Generalised structural equation multilevel models were used to assess factors associated with receiving medicines and having poorly controlled asthma in each age group. Findings Overall, 453 473 individuals from 63 centres in 25 countries were included, comprising 101 777 children (6445 [6·3%] with asthma diagnosed by a doctor), 157 784 adolescents (12 532 [7·9%]), and 193 912 adults (6677 [3·4%]). Use of asthma medicines varied by symptom severity and country income category. The most used medicines in the previous year were inhaled short-acting β2 agonists (SABA; range across age groups, 29·3–85·3% participants) and inhaled corticosteroids (12·6–51·9%). The proportion of individuals with severe asthma symptoms not taking inhaled corticosteroids (inhaled corticosteroids alone or with long-acting β2 agonists) was high in all age groups (934 [44·8%] of 2085 children, 2011 [60·1%] of 3345 adolescents, and 1142 [55·5%] of 2058 adults), ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISSN: |
2214-109X |
| Relation: |
https://openaccess.sgul.ac.uk/id/eprint/114975/6/1-s2.0-S2214109X2200506X-main.pdf; https://openaccess.sgul.ac.uk/id/eprint/114975/11/1-s2.0-S2214109X2200506X-mmc1.pdf; https://openaccess.sgul.ac.uk/id/eprint/114975/16/1-s2.0-S2214109X2200506X-mmc2.pdf; García-Marcos, L; Chiang, C-Y; Asher, MI; Marks, GB; El Sony, A; Masekela, R; Bissell, K; Ellwood, E; Ellwood, P; Pearce, N; et al. García-Marcos, L; Chiang, C-Y; Asher, MI; Marks, GB; El Sony, A; Masekela, R; Bissell, K; Ellwood, E; Ellwood, P; Pearce, N; Strachan, DP; Mortimer, K; Morales, E; Global Asthma Network Phase I Study Group (2023) Asthma management and control in children, adolescents and adults: Global Asthma Network (GAN) Phase I cross-sectional study. The Lancet Global Health, 11 (2). e218-e228. ISSN 2214-109X https://doi.org/10.1016/S2214-109X(22)00506-X SGUL Authors: Strachan, David Peter |
| DOI: |
10.1016/S2214-109X(22)00506-X |
| Availability: |
https://openaccess.sgul.ac.uk/id/eprint/114975/; https://doi.org/10.1016/S2214-109X(22)00506-X |
| Rights: |
cc_by_nc_nd_4 |
| Accession Number: |
edsbas.62BCE7F3 |
| Database: |
BASE |